Amgen Announces Positive Topline Phase 2 Results For Investigational KRAS G12C Inhibitor Sotorasib In Advanced Non-Small Cell Lung Cancer

THOUSAND OAKS, Calif., Oct. 5, 2020 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive topline Phase 2 results from the CodeBreaK 100 clinical study, evaluating sotorasib (proposed INN for AMG 510) in 126 patients...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials